High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4(+) and CD8(+) T-Cell Epitopes

The efficacy of an antitumoral vaccine relies both on the choice of the antigen targeted and on its design. The tumor antigen survivin is an attractive target to develop therapeutic cancer vaccines because of its restricted over-expression and vital functions in most human tumors. Accordingly, sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Onodi, Fanny, Maherzi-Mechalikh, Chahrazed, Mougel, Alice, Ben Hamouda, Nadine, Taboas, Charlotte, Gueugnon, Fabien, Tran, Thi, Nozach, Herve, Marcon, Elodie, Gey, Alain, Terme, Magali, Bouzidi, Ahmed, Maillere, Bernard, Kerzerho, Jérôme, Tartour, Eric, Tanchot, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243131/
https://www.ncbi.nlm.nih.gov/pubmed/30483475
http://dx.doi.org/10.3389/fonc.2018.00517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243131/
https://www.ncbi.nlm.nih.gov/pubmed/30483475
http://dx.doi.org/10.3389/fonc.2018.00517

Ejemplares similares